nano-cap

Portage Biotech Inc. (NASDAQ:PRTG) on Thursday presented new preclinical data for PORT-7 (TT-4), a selective Adenosine A2B receptor inhibitor, at the 2025 European Lung Cancer Congress. The new data demonstrate both single-agent activity for PORT-7 and a dramatic >90% inhibition of tumor...